Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to
public health since its emergence in late 2019. From a safety point of view, drug repurposing …

Growing evidence suggests an association between inflammatory processes and
depressive disorders (DD). DD typically emerge during adolescence. Treatment effects of …

The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is
a matter of debate since the beginning of the pandemic. To date, controversial results have …

Introduction Psychological, socio-demographics, and clinical factors play an important role
in patients with COVID-19, but their relationship is complex. The network approach might be …

Abstract The World Health Organization has proposed that a search be made for alternatives
to vaccines for the prevention and treatment of COVID-19, with one such alternative being …

Objective To examine differences in mortality and/or severe acute respiratory syndrome
between selective serotonin reuptake inhibitor-(SSRI) users and non-SSRI users up to 60 …

Background Reports at the beginning of the COVID-19 pandemic suggested differences in
COVID-19-associated mortality between individuals with serious mental disorders (SMD) …

Epidemiology has repeatedly associated certain infections with a risk of further develo**
psychiatric diseases. Such infections can activate retro-transposable genetic elements …

The objective of this study is to quantify the impact of the COVID-19 pandemic on attention
deficit hyperactivity disorder (ADHD) medication consumption globally and nationally using …

Fluvoxamine, a selective serotonin reuptake inhibitor with anti-inflammatory properties, has
gained attention as a repurposed drug to treat COVID-19. We aimed to explore the potential …